Biotech set to regain favour after recent thrills and spills

By Brian Robins
Updated January 22 2017 - 8:13pm, first published 7:08pm
CSL manufacturing assistant Lanie Hynninen at its biotech manufacturing facility in Melbourne. Photo: Mal Fairclough
CSL manufacturing assistant Lanie Hynninen at its biotech manufacturing facility in Melbourne. Photo: Mal Fairclough

The last few months have been ones to forget for biotech shares with a rotation of funds out of the sector globally leaving many stocks in the sector well down on their 12-month highs, with sentiment also hurt amid caution the US will force drug prices lower which will hit earnings.

Get the latest Katoomba news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.